FRANKFURT, Germany: German vaccine maker BioNTech on Wednesday reported a multibillion-euro windfall in 2021 from sales of its anti-coronavirus jab, developed together with United States pharmaceutical giant Pfizer.
Mainz-based BioNTech made a net income of 10.3 billion euros ($11.5 billion) last year, up from 15 million euros in 2020, the first year of the Covid-19 pandemic.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.